Stelara's negotiated price and its first biosimilar launch land in the same month. That collision, not either force alone, is the pricing event this model is built to quantify.
IRA negotiation has already reset the legacy biologic tier in psoriasis. CMS's negotiated Maximum Fair Price for Stelara (ustekinumab), on a 30-day equivalent basis, is $4,695 against a $13,836 list, a 66% cut, effective January 1 2026. Enbrel (etanercept) is cut similarly: $2,355 negotiated against a $7,106 list, a 67% reduction, effective the same date. Both cuts land on agents that have already been on the market for years and carried established payer contracts built around list-minus-rebate economics; the negotiated price replaces that entire structure at once.
The second shock lands on the same calendar. Nine to ten adalimumab biosimilars launched in 2023 and have already reshaped the TNF-inhibitor tier (Humira's own franchise). Ustekinumab biosimilars begin launching from January 2025, meaning Stelara faces biosimilar erosion in the same window as its IRA-negotiated price takes effect. A pricing strategy that models the IRA cut in isolation, without the biosimilar entry hitting the same product in the same period, will misprice the actual net-revenue trajectory; the two forces compound rather than offset.
ICER's 2018 assessment gives the value-based ceiling this class has been measured against since before either shock: cost-per-QALY ranged from roughly $131,000 for brodalumab to $188,000 for certolizumab pegol across the biologic class, and ICER's report explicitly recommended that payers limit or abolish step therapy requirements for these agents. That step-therapy recommendation matters directly for pricing strategy: any negotiated-price or biosimilar-entry model has to account for whether payer utilization management is loosening or holding, since UM policy changes the effective volume each price point actually reaches.
US psoriasis pricing — IRA-negotiated price and biosimilar erosion timeline compared
| Agent | List Price (30-day equiv.) | IRA-Negotiated MFP | Discount | Concurrent Biosimilar Event |
|---|---|---|---|---|
| Stelara (ustekinumab) | $13,836 | $4,695 (eff. Jan 1 2026) | 66% | Ustekinumab biosimilars launching from Jan 2025 |
| Enbrel (etanercept) | $7,106 | $2,355 (eff. Jan 1 2026) | 67% | No direct biosimilar to etanercept in this class wave |
| Humira (adalimumab, comparator precedent) | N/A, not IRA-negotiated in this cycle | N/A | N/A | 9-10 biosimilars launched 2023, the erosion-speed precedent |
Sources: CMS Medicare Drug Price Negotiation Program, IPAY 2026 selected-drug list and Maximum Fair Price announcement; FDA Purple Book biosimilar approval and launch tracking; ICER Institute for Clinical and Economic Review, psoriasis biologic therapies assessment, 2018.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Agent-by-agent MFP vs list comparison for both negotiated agents
- The January 1 2026 effective-date mechanics
- A gross-to-net waterfall showing where existing rebate contracts sit relative to the negotiated floor
Delivers
- The 2023 adalimumab biosimilar precedent as the comparator class
- Ustekinumab biosimilar launch timing from January 2025
- A compounded erosion scenario versus a negotiation-only or biosimilar-only scenario
Delivers
- ICER's 2018 cost-per-QALY range across the biologic class
- ICER's step-therapy limitation/abolition recommendation and its access implications
- How negotiated pricing changes the value-based case for looser utilization management
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the collision of IRA negotiation and biosimilar entry on the same product and timeline, not either force alone, is the pricing event to model
- Pressure-tested against Stelara's negotiated price and biosimilar launch date before the rest of the model is built out
- The $4,695 Stelara and $2,355 Enbrel Maximum Fair Prices and January 1 2026 effective date
- 66-67% discount mechanics against 30-day-equivalent list
- The 2023 adalimumab biosimilar precedent (9-10 entrants)
- Ustekinumab biosimilar launch timing from January 2025 and its overlap with the IRA effective date
- Why negotiation-only and biosimilar-only models understate net-revenue erosion
- A combined scenario tracking both forces on the same timeline
- 2018 cost-per-QALY range across the biologic class ($131K-$188K)
- ICER's step-therapy limitation/abolition recommendation and its access implications
- Gross-to-net build from list to net for Stelara and Enbrel under the negotiated price
- Where existing commercial rebates now sit relative to the negotiated floor
- Conservative, base, and aggressive scenarios tied to biosimilar uptake speed and negotiation-cycle expansion
- Sensitivity ranking of biosimilar entry timing versus negotiated-price depth
- The open pricing questions your team must close before a psoriasis contracting position is locked
- Explicit flag: growth-brand (Skyrizi, Tremfya, Bimzelx) pricing is a known gap for a future update, not modeled here
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model for a biologic facing simultaneous negotiation and biosimilar entry tracks both forces on one timeline rather than modeling them independently, since a single-shock model consistently understates the actual net-revenue trajectory.
Psoriasis US pricing sources: CMS Medicare Drug Price Negotiation Program IPAY 2026 announcement, FDA Purple Book biosimilar approval and launch tracking for both adalimumab and ustekinumab biosimilars, and the ICER psoriasis biologic therapies value assessment, 2018.
- Stelara's $4,695 negotiated price, $13,836 list, and 66% discount verified against the CMS IPAY 2026 selected-drug list and negotiated price announcement
- Enbrel's $2,355 negotiated price, $7,106 list, and 67% discount verified against the same CMS IPAY 2026 announcement
- The 2023 adalimumab biosimilar count (9-10 launches) and the ustekinumab biosimilar January 2025 launch window verified against FDA Purple Book biosimilar tracking
- ICER's 2018 cost-per-QALY range ($131,000-$188,000) and step-therapy recommendation verified against ICER's published 2018 psoriasis biologic therapies assessment
- Growth-brand agents (Skyrizi, Tremfya, Bimzelx) pricing is explicitly out of scope for this model and flagged as a gap for a future update rather than estimated
Frequently asked questions
Commission this model
AXLRx delivers psoriasis pricing strategy models built for market access and pricing teams navigating IRA negotiation and biosimilar erosion landing together. Custom model in 72 hours.
Specify your target payer channel, plan mix, and comparator agents.
AXLRx analyst confirms negotiation-cycle and biosimilar-wave assumptions, plus any growth-brand comparator scope, before building.
Research-verified pricing model in 72 hours with optional analyst readout.